## **Choon H Chung**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7728984/publications.pdf

Version: 2024-02-01

125106 214428 3,276 108 35 50 citations g-index h-index papers 109 109 109 5799 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation. Endocrinology and Metabolism, 2022, 37, 96-111.	1.3	2
2	Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 1495-1503.	1.1	1
3	Curcumin Blocks High Glucose-Induced Podocyte Injury via RIPK3-Dependent Pathway. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	9
4	RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death. Cells, 2021, 10, 245.	1.8	8
5	Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy. PLoS ONE, 2021, 16, e0250666.	1.1	14
6	Tetrahydrocurcumin Ameliorates Skin Inflammation by Modulating Autophagy in High-Fat Diet-Induced Obese Mice. BioMed Research International, 2021, 2021, 1-8.	0.9	7
7	Dehydrozingerone inhibits renal lipotoxicity in highâ€fat diet–induced obese mice. Journal of Cellular and Molecular Medicine, 2021, 25, 8725-8733.	1.6	12
8	Tetrahydrocurcumin Ameliorates Kidney Injury and High Systolic Blood Pressure in High-Fat Diet-Induced Type 2 Diabetic Mice. Endocrinology and Metabolism, 2021, 36, 810-822.	1.3	5
9	Curcumin analog CUR5–8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity. Metabolism: Clinical and Experimental, 2020, 103, 154015.	1.5	62
10	APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice. Free Radical Biology and Medicine, 2020, 161, 92-101.	1.3	13
11	The myokine meteorinâ€like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2. FEBS Journal, 2020, 287, 2087-2104.	2.2	40
12	A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2020, 34, 107555.	1.2	13
13	Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, activeâ€controlled, randomized, doubleâ€blind study with openâ€label extension (the EVERGREEN study). Diabetes, Obesity and Metabolism, 2020, 22, 1527-1536.	2.2	13
14	CCR2 knockout ameliorates obesity-induced kidney injury through inhibiting oxidative stress and ER stress. PLoS ONE, 2019, 14, e0222352.	1.1	25
15	Cur2004-8, a synthetic curcumin derivative, extends lifespan and modulates age-related physiological changes in < >Caenorhabditis elegans < i>Drug Discoveries and Therapeutics, 2019, 13, 198-206.	0.6	7
16	Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease. Scientific Reports, 2019, 9, 7679.	1.6	44
17	Exposure to pesticides and the prevalence of diabetes in a rural population in Korea. NeuroToxicology, 2019, 70, 12-18.	1.4	37
18	Dibenzoylmethane ameliorates lipid-induced inflammation and oxidative injury in diabetic nephropathy. Journal of Endocrinology, 2019, 240, 169-179.	1.2	17

#	Article	IF	Citations
19	Metabolic changes in urine and serum during progression of diabetic kidney disease in a mouse model. Archives of Biochemistry and Biophysics, 2018, 646, 90-97.	1.4	11
20	A 52â€week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as addâ€on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone. Diabetes, Obesity and Metabolism, 2018, 20, 1535-1541.	2.2	3
21	Dual CCR2/5 Antagonist Attenuates Obesityâ€Induced Insulin Resistance by Regulating Macrophage Recruitment and M1/M2 Status. Obesity, 2018, 26, 378-386.	1.5	23
22	Effect of a short-term physical activity intervention on liver fat content in obese children. Applied Physiology, Nutrition and Metabolism, 2018, 43, 553-557.	0.9	2
23	Caffeic acid ameliorates hepatic steatosis and reduces ER stress in high fat diet–induced obese mice by regulating autophagy. Nutrition, 2018, 55-56, 63-70.	1.1	54
24	Rice bran protein hydrolysates attenuate diabetic nephropathy in diabetic animal model. European Journal of Nutrition, 2018, 57, 761-772.	1.8	26
25	Impaired permeability and antimicrobial barriers in type 2 diabetes skin are linked to increased serum levels of advanced glycation endâ€product. Experimental Dermatology, 2018, 27, 815-823.	1.4	37
26	An Unusual Case of Meningioma Showing Increased CaSR Expression with Parathyroid Carcinoma. Endocrinology and Metabolism, 2018, 33, 133.	1.3	0
27	Efficacy and safety of ipragliflozin as an addâ€on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 2408-2415.	2.2	30
28	Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus. Journal of Diabetes, 2017, 9, 396-404.	0.8	5
29	Efficacy and safety of adding evogliptin versus sitagliptin for metforminâ€treated patients with type 2 diabetes: <scp>A</scp> 24â€week randomized, controlled trial with open label extension. Diabetes, Obesity and Metabolism, 2017, 19, 654-663.	2.2	24
30	Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes, Obesity and Metabolism, 2017, 19, 1681-1687.	2.2	21
31	Efficacy and safety of gemigliptin, a dipeptidyl peptidaseâ€4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: <scp>a</scp> 24â€week, multicentre, randomized, doubleâ€blind, placeboâ€controlled study ( <scp>TROICA</scp> study). Diabetes, Obesity and Metabolism, 2017, 19, 635-643.	2.2	11
32	Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism: Clinical and Experimental, 2017, 66, 23-31.	1.5	55
33	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. International Journal of Clinical Practice, 2017, 71, e12987.	0.8	4
34	Relationship between Regional Body Fat Distribution and Diabetes Mellitus: 2008 to 2010 Korean National Health and Nutrition Examination Surveys. Diabetes and Metabolism Journal, 2017, 41, 51.	1.8	39
35	$\hat{l}_{\pm}$ -Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2. PLoS ONE, 2017, 12, e0179204.	1.1	20
36	Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice. PLoS ONE, 2017, 12, e0179221.	1.1	18

#	Article	IF	CITATIONS
37	Combined Effect of Initial and Longitudinal Increases in Î <sup>3</sup> -Glutamyltransferase on Incident Metabolic Syndrome: ARIRANG Study. Yonsei Medical Journal, 2017, 58, 763.	0.9	7
38	Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks. Diabetes and Metabolism Journal, 2017, 41, 377.	1.8	21
39	Protective Effects of Curcumin on Renal Oxidative Stress and Lipid Metabolism in a Rat Model of Type 2 Diabetic Nephropathy. Yonsei Medical Journal, 2016, 57, 664.	0.9	88
40	Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin–Angiotensin System Blockade. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2108-2114.	1.1	6
41	High Serum Irisin Level as an Independent Predictor of Diabetes Mellitus. Medicine (United States), 2016, 95, e3742.	0.4	37
42	Decreased plasma $\hat{l}$ ±-Klotho predict progression of nephropathy with type 2 diabetic patients. Journal of Diabetes and Its Complications, 2016, 30, 887-892.	1.2	51
43	Oleanolic acid and $\langle i \rangle N \langle i \rangle$ -acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrology Dialysis Transplantation, 2016, 31, 391-400.	0.4	77
44	Basalâ€prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24â€week randomized nonâ€inferiority trial. Journal of Diabetes, 2016, 8, 405-413.	0.8	21
45	Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. Diabetes Research and Clinical Practice, 2015, 110, e27-e30.	1.1	25
46	Dehydrozingerone exerts beneficial metabolic effects in highâ€fat dietâ€induced obese mice <i>via </i> <scp>AMPK</scp> activation in skeletal muscle. Journal of Cellular and Molecular Medicine, 2015, 19, 620-629.	1.6	9
47	A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. Endocrine Journal, 2015, 62, 449-462.	0.7	14
48	Maternal Age at First Delivery Is Associated with the Risk of Metabolic Syndrome in Postmenopausal Women: From 2008–2010 Korean National Health and Nutrition Examination Survey. PLoS ONE, 2015, 10, e0127860.	1.1	21
49	High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS ONE, 2015, 10, e0143222.	1.1	38
50	Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis, 2015, 241, 271-277.	0.4	53
51	Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetology and Metabolic Syndrome, 2015, 7, 64.	1.2	23
52	Gender-specific association between urinary sodium excretion and body composition: Analysis of the 2008–2010 Korean National Health and Nutrition Examination Surveys. Metabolism: Clinical and Experimental, 2015, 64, 837-844.	1.5	22
53	Effects of Tumor Necrosis Factor- $\hat{l}_{\pm}$ on Podocyte Expression of Monocyte Chemoattractant Protein-1 and in Diabetic Nephropathy. Nephron Extra, 2015, 5, 1-18.	1.1	36
54	Serum cystatin C levels are associated with asymptomatic peripheral arterial disease in type 2 diabetes mellitus patients without overt nephropathy. Diabetes Research and Clinical Practice, 2015, 108, 258-264.	1.1	11

#	Article	IF	CITATIONS
55	Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea. BMJ Open, 2015, 5, e006898-e006898.	0.8	16
56	Palmitate induces ER calcium depletion and apoptosis in mouse podocytes subsequent to mitochondrial oxidative stress. Cell Death and Disease, 2015, 6, e1976-e1976.	2.7	148
57	Dibenzoylmethane Exerts Metabolic Activity through Regulation of AMP-Activated Protein Kinase (AMPK)-Mediated Glucose Uptake and Adipogenesis Pathways. PLoS ONE, 2015, 10, e0120104.	1.1	15
58	C-C Chemokine Receptor 2 Inhibitor Ameliorates Hepatic Steatosis by Improving ER Stress and Inflammation in a Type 2 Diabetic Mouse Model. PLoS ONE, 2015, 10, e0120711.	1.1	21
59	Lower Serum Creatinine Is Associated with Low Bone Mineral Density in Subjects without Overt Nephropathy. PLoS ONE, 2015, 10, e0133062.	1.1	28
60	Soluble α-Klotho as a Novel Biomarker in the Early Stage of Nephropathy in Patients with Type 2 Diabetes. PLoS ONE, 2014, 9, e102984.	1.1	57
61	Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer. Annals of Surgical Treatment and Research, 2014, 86, 55.	0.4	31
62	Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study. Journal of Korean Medical Science, 2014, 29, 90.	1.1	41
63	Taurine Alleviates the Progression of Diabetic Nephropathy in Type 2 Diabetic Rat Model. International Journal of Endocrinology, 2014, 2014, 1-11.	0.6	28
64	Efficacy of glimepiride/metformin fixedâ€dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on lowâ€dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in <scp>K</scp> orea. Journal of Diabetes Investigation, 2014, 5, 701-708.	1.1	23
65	Upregulation of mitochondrial Nox4 mediates TGF- $\hat{l}^2$ -induced apoptosis in cultured mouse podocytes. American Journal of Physiology - Renal Physiology, 2014, 306, F155-F167.	1.3	89
66	Umbelliferone Increases the Expression of Adipocyteâ€Specific Genes in 3 T3‣1 Adipocyte. Phytotherapy Research, 2014, 28, 1671-1675.	2.8	4
67	Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial. PLoS ONE, 2014, 9, e92843.	1.1	55
68	Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrology Dialysis Transplantation, 2013, 28, 1700-1710.	0.4	90
69	Diabetes Epidemics in Korea: Reappraise Nationwide Survey of Diabetes "Diabetes in Korea 2007". Diabetes and Metabolism Journal, 2013, 37, 233.	1.8	65
70	Prevalence of Metabolic Syndrome in Type 2 Diabetes Mellitus Using NCEP-ATPIII, IDF and WHO Definition and Its Agreement in Gwalior Chambal Region of Central India. Global Journal of Health Science, 2013, 5, 142-55.	0.1	66
71	Peroxisome proliferator-activated receptor $\hat{l}$ agonist attenuates hepatic steatosis by anti-inflammatory mechanism. Experimental and Molecular Medicine, 2012, 44, 578.	3.2	50
72	Peroxisome proliferator-activated receptor-Â activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in Type 2 diabetes. Nephrology Dialysis Transplantation, 2012, 27, 4069-4079.	0.4	24

#	Article	IF	Citations
73	Mulberry leaf extract increases adiponectin in murine 3T3-L1 adipocytes. Nutrition Research, 2012, 32, 39-44.	1.3	49
74	The association between pentraxin 3 and insulin resistance in obese children at baseline and after physical activity intervention. Clinica Chimica Acta, 2012, 413, 1430-1437.	0.5	27
75	Role of HbA1c in the Screening of Diabetes Mellitus in a Korean Rural Community. Diabetes and Metabolism Journal, 2012, 36, 37.	1.8	14
76	Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes. Experimental and Molecular Medicine, 2011, 43, 676.	3.2	115
77	Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Research and Clinical Practice, 2011, 94, 156-162.	1.1	50
78	Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model. Diabetes and Metabolism Journal, 2011, 35, 130.	1.8	17
79	A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process. Experimental Dermatology, 2011, 20, 969-974.	1.4	61
80	Inverse Association Between Total Bilirubin and Metabolic Syndrome in Rural Korean Women. Journal of Women's Health, 2011, 20, 963-969.	1.5	33
81	Optimal Waist Circumference Cutoff Values for Metabolic Syndrome Diagnostic Criteria in a Korean Rural Population. Journal of Korean Medical Science, 2010, 25, 734.	1.1	21
82	Aldose Reductase Inhibitor Ameliorates Renal Vascular Endothelial Growth Factor Expression in Streptozotocin-Induced Diabetic Rats. Yonsei Medical Journal, 2010, 51, 385.	0.9	13
83	Association between alcohol intake amount and prevalence of metabolic syndrome in Korean rural male population. Diabetes Research and Clinical Practice, 2010, 88, 196-202.	1.1	18
84	The monocyte chemoattractant protein- $1/CCR2$ loop, inducible by TGF- $\hat{i}^2$ , increases podocyte motility and albumin permeability. American Journal of Physiology - Renal Physiology, 2009, 297, F85-F94.	1.3	121
85	Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 147-152.	4.3	61
86	Relationships between adiponectin and the status of glucose metabolism in Koreans. Toxicology and Environmental Health Sciences, 2009, 1, 69-73.	1.1	0
87	Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: The role of reducing oxidative stress in its protective property. Diabetes Research and Clinical Practice, 2009, 83, 176-182.	1.1	46
88	Elevated serum $\hat{I}^3$ -glutamyltransferase levels are independently associated with insulin resistance in non-diabetic subjects. Diabetes Research and Clinical Practice, 2009, 84, 152-157.	1.1	27
89	Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes. Yonsei Medical Journal, 2008, 49, 901.	0.9	10
90	Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice, 2007, 77, S247-S251.	1.1	47

#	Article	IF	Citations
91	Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology, 2007, 66, 282-289.	1.2	64
92	Blockade of Oxidative Stress by Vitamin C Ameliorates Albuminuria and Renal Sclerosis in Experimental Diabetic Rats. Yonsei Medical Journal, 2007, 48, 847.	0.9	49
93	Beneficial Effects of Thiazolidinediones on Diabetic Nephropathy in OLETF Rats. Yonsei Medical Journal, 2007, 48, 301.	0.9	14
94	Current Status of Diabetes Management in Korea Using National Health Insurance Database. The Journal of Korean Diabetes Association, 2007, 31, 362.	0.1	32
95	The Role of Glomerular Podocytes in Diabetic Nephropathy. The Journal of Korean Diabetes Association, 2007, 31, 451.	0.1	4
96	The Effect of Rosiglitazone on Gluose Metabolism and Insulin Sensitivity in Non Obese Type 2 Diabetic Rat Models. The Journal of Korean Diabetes Association, 2007, 31, 319.	0.1	0
97	Current Status of Diabetic Foot in Korean Patients Using National Health Insurance Database. The Journal of Korean Diabetes Association, 2006, 30, 372.	0.1	19
98	Current Status of Diabetic End-Stage Renal Disease Using Korean Health Insurance Database. The Journal of Korean Diabetes Association, 2006, 30, 355.	0.1	7
99	Current Status of the Continuity of Ambulatory Diabetes Care and its Impact on Health Outcomes and Medical Cost in Korea Using National Health Insurance Database. The Journal of Korean Diabetes Association, 2006, 30, 377.	0.1	24
100	Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrology Dialysis Transplantation, 2006, 21, 1496-1503.	0.4	40
101	Anti-Diabetic Effect of Alkaline-Reduced Water on OLETF Rats. Bioscience, Biotechnology and Biochemistry, 2006, 70, 31-37.	0.6	41
102	Recurrent Acute Pancreatitis in a Patient with Type IIb hyperlipoproteinemia: A Case Report and Review of the Literature in Korea. Yonsei Medical Journal, 2006, 47, 144.	0.9	4
103	Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice. Yonsei Medical Journal, 2005, 46, 341.	0.9	6
104	A Case of Autoimmune Hypoglycemia Complicated with Diabetic Ketoacidosis. Yonsei Medical Journal, 2004, 45, 140.	0.9	6
105	Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Experimental and Molecular Medicine, 2004, 36, 65-70.	3.2	40
106	Immunoglobulin A nephropathy in patients with non-insulin dependent diabetes mellitus. Journal of Korean Medical Science, 1999, 14, 582.	1.1	4
107	Non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Yonsei Medical Journal, 1999, 40, 321.	0.9	52
108	IGF-I of serum and vitreous fluid in patients with diabetic proliferative retinopathy. Diabetes Research and Clinical Practice, 1994, 24, 85-88.	1.1	16